2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes
2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes
复制标题
DOI：
10.3322/caac.21357
复制
发表时间：
2016-11-01
影响因子：
254.7
通讯作者：
Flowers, Christopher R.
中科院分区：
文献类型：
--
作者：
Teras, Lauren R.;DeSantis, Carol E.;Flowers, Christopher R.
总体而言，淋巴肿瘤是美国第四大常见癌症和第六大癌症死亡原因。作者提供了基于2008年世界卫生组织分类的亚型的当代淋巴瘤统计数据，包括最新的美国发病率和生存数据。第一次提出了美国淋巴瘤病例总数的估计亚型以及发病率和生存统计的详细评价。2016年，预计将有136，960例新发淋巴肿瘤。近年来，淋巴瘤的总体发病率有所下降，但趋势因亚型而异。2001年至2012年，前体淋巴肿瘤的发病率有所增加，特别是B细胞肿瘤。在成熟淋巴肿瘤中，浆细胞肿瘤增长最快。套细胞淋巴瘤（雄性）、边缘区淋巴瘤、毛细胞白血病和蕈样霉菌病的发生率也增加。与发病率一样，成熟T细胞淋巴瘤和成熟B细胞淋巴瘤的生存率也因亚型和种族而异。外周T细胞淋巴瘤患者的5年相对生存率最低（36%-56%，取决于种族/性别），而蕈样肉芽肿患者的5年相对生存率最高（79%-92%）。对于B细胞淋巴瘤，边缘区淋巴瘤患者的5年生存率为83%至91%，毛细胞白血病患者的5年生存率为78%至92%;但伯基特淋巴瘤患者的5年生存率低至47%至63%，浆细胞肿瘤患者的5年生存率为44%至48%。一般来说，黑人男性在淋巴恶性肿瘤亚型中的生存率最低。这些当代的发病率和生存率统计数据对于制定这些癌症的管理策略是有用的，并且可以提供有关其病因的线索。(C)2016美国癌症协会
Collectively, lymphoid neoplasms are the fourth most common cancer and the sixth leading cause of cancer death in the United States. The authors provide contemporary lymphoid neoplasm statistics by subtype based on the 2008 World Health Organization classifications, including the most current US incidence and survival data. Presented for the first time are estimates of the total numbers of US lymphoid neoplasm cases by subtype as well as a detailed evaluation of incidence and survival statistics. In 2016, 136,960 new lymphoid neoplasms are expected. Overall lymphoma incidence rates have declined in recent years, but trends vary by subtype. Precursor lymphoid neoplasm incidence rates increased from 2001 to 2012, particularly for B-cell neoplasms. Among the mature lymphoid neoplasms, the fastest increase was for plasma cell neoplasms. Rates also increased for mantle cell lymphoma (males), marginal zone lymphoma, hairy cell leukemia, and mycosis fungoides. Like incidence, survival for both mature T-cell lymphomas and mature B-cell lymphomas varied by subtype and by race. Patients with peripheral T-cell lymphomas had among the worst 5-year relative survival (36%-56%, depending on race/sex), while those with mycosis fungoides had among the best survival (79%-92%). For B-cell lymphomas, 5-year survival ranged from 83% to 91% for patients with marginal zone lymphoma and from 78% to 92% for those with hairy cell leukemia; but the rates were as low as 47% to 63% for patients with Burkitt lymphoma and 44% to 48% for those with plasma cell neoplasms. In general, black men had the lowest survival across lymphoid malignancy subtypes. These contemporary incidence and survival statistics are useful for developing management strategies for these cancers and can offer clues regarding their etiology. (C) 2016 American Cancer Society.